Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

Author(s):

Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond

Now Viewing

EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

Video content above is prompted by the following:

An ASH abstract from the group at Sylvester Comprehensive Cancer Center highlighted the potential of using tocilizumab prophylactically to mitigate CRS in patients treated with bispecific therapies for multiple myeloma. What are your thoughts on this approach, and how might it change current CRS prevention protocols?
Talquetamab has unique toxicities such as nail changes, skin reactions, and oral complications. What are your recommendations for effectively managing these adverse events?